Clinical and imaging efficacy of infliximab in HLA-B27-Positive patients with magnetic resonance imaging-determined early sacroiliitis.

Abstract

OBJECTIVE:

To evaluate the efficacy of infliximab in HLA-B27-positive patients with magnetic resonance imaging (MRI)-determined early sacroiliitis, using both clinical and MRI assessments.

METHODS:

Forty patients with recent-onset inflammatory back pain, as assessed by the Calin criteria, HLA-B27 positivity, clinical disease activity as measured by the Bath Ankylosing Spondylitis Disease Activity Index (BASDAI), pain and morning stiffness, and magnetic resonance imaging (MRI)-determined sacroiliac joint bone edema were randomized in a double-blind manner to receive infliximab 5 mg/kg or placebo at 0, 2, 6, and 12 weeks. MRI scans were performed at baseline and 16 weeks and scored by 2 observers (blinded to both the order of the scans and to treatment group), using the Leeds scoring system. Clinical assessments included the BASDAI, the Bath Ankylosing Spondylitis Functional Index (BASFI), the Ankylosing Spondylitis Quality of Life (ASQoL) instrument, the ASsessment in Ankylosing Spondylitis International Working Group criteria (ASAS) for improvement, and markers of inflammation.

RESULTS:

The mean reduction in the total MRI score from week 0 to week 16 was significantly greater in infliximab-treated patients compared with placebo-treated patients (P = 0.033). On average, significantly more lesions resolved in the infliximab group (P < 0.001), while significantly more new lesions developed in the placebo group (P = 0.004). Significantly greater improvement in the infliximab group versus the placebo group was also observed for changes from week 0 to week 16 in the BASDAI (P = 0.002), BASFI (P = 0.004), and ASQoL (P = 0.007) scores. Responses according to the ASAS criteria for 40% improvement, the ASAS criteria for 20% improvement in 5 of 6 domains, and ASAS partial remission were achieved by 61%, 44%, and 56% of infliximab-treated patients, respectively. Infliximab was well tolerated, and no serious adverse events were observed.

CONCLUSION:

Infliximab was an effective therapy for early sacroiliitis, providing a reduction in disease activity by week 16. This study is the first to show that infliximab is effective for reducing clinical and imaging evidence of disease activity in patients with MRI-determined early axial spondylarthritis.

• Authors: Nick Barkham, Helen I Keen, Laura C Coates, Philip O'Connor, Elizabeth Hensor, Alexander D Fraser, Lorna S Cawkwell, Alexander Bennett, Dennis McGonagle, Paul Emery
• Journal: Arthritis and rheumatism (Arthritis Rheum) Vol. 60 Issue 4 Pg. 946-54 (Apr 2009) ISSN: 0004-3591 [Print] United States
• PMID: 19333933 (Publication Type: Journal Article, Randomized Controlled Trial, Research Support, Non-U.S. Gov't)

Chemical References

• Antibodies, Monoclonal
• Antirheumatic Agents
• HLA-B27 Antigen
• Infliximab

Topics

• Adult
• Antibodies, Monoclonal (administration & dosage, adverse effects)
• Antirheumatic Agents (administration & dosage, adverse effects)
• Disability Evaluation
• Early Diagnosis
• Female
• HLA-B27 Antigen (immunology)
• Humans
• Infliximab
• Low Back Pain (drug therapy, immunology, pathology)
• Magnetic Resonance Imaging
• Male
• Sacroiliac Joint (immunology, pathology)
• Spondylarthritis (drug therapy, immunology, pathology)
• Treatment Outcome